Entasis Therapeutics
Entasis Therapeutics develops novel anti-infective therapies for drug-resistant infections, including the FDA-approved XACDURO for Acinetobacter. Now operating as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva.
- Company typePrivate
- Founded2015
- HeadquartersWaltham, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Entasis Therapeutics does
Entasis Therapeutics is a clinical-stage biopharmaceutical company that developed novel anti-infective therapies targeting serious, life-threatening infections caused by drug-resistant microorganisms, with particular focus on critical care and hospital-acquired infections. Founded in 2015 and headquartered in Waltham, Massachusetts, the company built a portfolio around proprietary small-molecule approaches to overcoming bacterial resistance, most notably XACDURO (sulbactam-durlobactam), an FDA-approved antimicrobial combination therapy for the treatment of Acinetobacter baumannii-calcoaceticus complex infections. The company raised approximately $199.5 million across multiple private and public funding rounds between 2015 and 2021, with investors including Clarus Ventures, Eventide, Frazier Healthcare Partners, Novo Holdings, Pivotal bioVenture Partners, Sofinnova Investments, TPG, and CARB-X.
The company was acquired by Innoviva, Inc. (NASDAQ: INVA), a diversified holding company that manages royalty streams from GlaxoSmithKline respiratory drugs (Trelegy Ellipta, Breo Ellipta) and reinvests those proceeds into specialty therapeutics acquisitions. Following the acquisition, Entasis operates as part of Innoviva Specialty Therapeutics, whose broader marketed portfolio includes GIAPREZA, NUZOLVENCE, XACDURO, XERAVA, and ZEVTERA. Products are distributed through traditional specialty pharmaceutical channels targeting hospital and clinical settings, with marketing and medical affairs activities focused on healthcare professional engagement and scientific exchange. The company's value proposition centers on addressing high-unmet-need infectious diseases identified as urgent threats by leading global public health organizations, with the Acinetobacter treatment market projected to reach $1.25 billion by 2032.
Entasis Therapeutics firmographics
Firmographics- Name
- Entasis Therapeutics
- Legal name
- Entasis Therapeutics
- Website
- https://entasistx.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 51–100 employees
- Short description
- Entasis Therapeutics develops novel anti-infective therapies for drug-resistant infections, including the FDA-approved XACDURO for Acinetobacter. Now operating as a subsidiary of Innoviva Specialty Therapeutics following acquisition by Innoviva.
- Ownership category
- akta.pro rank
Entasis Therapeutics industry classification
Industry- Product category
- Anti-Infective Pharmaceuticals
- NAICS
- Health Care and Social Assistance (62)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Respiratory & Allergy Pharmaceuticals (HLAIAAAH)
Keywords
Where Entasis Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Waltham
- HQ country
- United States
- HQ region
- North America
Markets served
Entasis Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Specialty Pharmaceutical Products: Revenue generated from the sale of specialty pharmaceutical products for critical care and infectious diseases, including products like Giapreza and Xacduro that were acquired through the company's acquisition by Innoviva.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Entasis Therapeutics product offering
Product offeringCore offering
Entasis Therapeutics develops and delivers specialty anti-infective pharmaceutical products targeting critical care and infectious disease, with a focus on therapies for serious, life-threatening infections caused by drug-resistant microorganisms. Its marketed products include XACDURO (sulbactam-durlobactam), GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XERAVA (eravacycline), and ZEVTERA (ceftobiprole), now commercialized through Innoviva Specialty Therapeutics following Innoviva's acquisition of Entasis.
Product overview
Entasis Therapeutics was a clinical-stage biopharmaceutical company focused on developing novel anti-infective products. The company was acquired by Innoviva (INVA), and its products including XACDURO are now marketed through Innoviva Specialty Therapeutics. The product portfolio includes therapies for critical care and infectious diseases caused by drug-resistant microorganisms.
Differentiator
Problem solved
Functional benefit
Products and services
- XACDURO (sulbactam for injection; durlobactam for injection) FDA-approved antimicrobial therapy combining sulbactam and durlobactam, developed to treat drug-resistant Acinetobacter baumannii-calcoaceticus complex infections in hospital and critical care settings. It is marketed through Innoviva Specialty Therapeutics and is for healthcare providers treating serious, life-threatening infections.
- GIAPREZA (angiotensin II) Critical care therapy for adult patients with distributive shock, marketed through Innoviva Specialty Therapeutics to hospital and clinical settings.
- NUZOLVENCE (zoliflodacin) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio for serious infectious diseases, distributed through standard hospital and clinical pharmaceutical channels.
- XERAVA (eravacycline) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for treatment of serious infections.
- ZEVTERA (ceftobiprole medocaril sodium for injection) Anti-infective therapy within the Innoviva Specialty Therapeutics portfolio, distributed through standard hospital and clinical pharmaceutical channels for serious infectious disease indications.
Companies that use Entasis Therapeutics
Customer profileSegments2 records
Ideal customer profiles1 record
Entasis Therapeutics technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Entasis Therapeutics partnerships and signals
Strategic signalScale indicators1 record
Recent moves6 records
Expansion highlights5 records
Entasis Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Customer concentration
Entasis Therapeutics social profiles
Digital presenceEntasis Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Entasis Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Entasis Therapeutics funding detail
Funding detailFunding overview
Funding rounds8 records
Investors8 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Entasis Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Entasis Therapeutics
What does Entasis Therapeutics do?
Entasis Therapeutics develops and delivers specialty anti-infective pharmaceutical products targeting critical care and infectious disease, with a focus on therapies for serious, life-threatening infections caused by drug-resistant microorganisms. Its marketed products include XACDURO (sulbactam-durlobactam), GIAPREZA (angiotensin II), NUZOLVENCE (zoliflodacin), XERAVA (eravacycline), and ZEVTERA (ceftobiprole), now commercialized through Innoviva Specialty Therapeutics following Innoviva's acquisition of Entasis.
Is Entasis Therapeutics a public or private company?
Entasis Therapeutics is a private company. It is classified as corporate owned and is currently acquired.
When was Entasis Therapeutics founded?
Entasis Therapeutics was founded in 2015. It employs 51 to 100 people.
Where is Entasis Therapeutics based?
Entasis Therapeutics is headquartered in Waltham, United States, in the North America region.
How does Entasis Therapeutics make money?
One revenue line is on record: specialty Pharmaceutical Products.
Does Entasis Therapeutics have an API?
No public API is recorded for Entasis Therapeutics.
What industry is Entasis Therapeutics in?
Entasis Therapeutics's product category is Anti-Infective Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAH, Respiratory & Allergy Pharmaceuticals. Its NAICS code is 62 and its SIC code is 3841.